Calithera Biosciences (CALA) Downgraded by BidaskClub to “Strong Sell”

BidaskClub lowered shares of Calithera Biosciences (NASDAQ:CALA) from a sell rating to a strong sell rating in a report published on Thursday.

A number of other analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Calithera Biosciences from a buy rating to a hold rating in a research report on Tuesday, January 2nd. ValuEngine lowered shares of Calithera Biosciences from a hold rating to a sell rating in a research report on Friday, December 1st. Finally, William Blair assumed coverage on shares of Calithera Biosciences in a research report on Thursday, October 5th. They issued an outperform rating on the stock. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of Hold and an average price target of $15.17.

Shares of Calithera Biosciences (NASDAQ:CALA) traded up $0.05 during trading hours on Thursday, hitting $8.40. 313,206 shares of the company were exchanged, compared to its average volume of 364,800. Calithera Biosciences has a 1 year low of $4.10 and a 1 year high of $20.05. The company has a market cap of $298.00, a P/E ratio of -8.48 and a beta of 2.87.

Calithera Biosciences (NASDAQ:CALA) last announced its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.17) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.06. The business had revenue of $7.20 million during the quarter, compared to the consensus estimate of $6.02 million. equities research analysts predict that Calithera Biosciences will post -0.77 EPS for the current year.

A number of institutional investors have recently bought and sold shares of the stock. Acadian Asset Management LLC raised its position in Calithera Biosciences by 1,279.5% in the 4th quarter. Acadian Asset Management LLC now owns 21,686 shares of the biotechnology company’s stock worth $181,000 after purchasing an additional 20,114 shares during the period. Schwab Charles Investment Management Inc. raised its position in Calithera Biosciences by 56.8% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 112,235 shares of the biotechnology company’s stock worth $938,000 after purchasing an additional 40,635 shares during the period. Franklin Street Advisors Inc. NC raised its position in Calithera Biosciences by 56.2% in the 4th quarter. Franklin Street Advisors Inc. NC now owns 55,580 shares of the biotechnology company’s stock worth $464,000 after purchasing an additional 20,000 shares during the period. California Public Employees Retirement System raised its position in Calithera Biosciences by 210.1% in the 3rd quarter. California Public Employees Retirement System now owns 43,719 shares of the biotechnology company’s stock worth $689,000 after purchasing an additional 29,619 shares during the period. Finally, Wells Fargo & Company MN raised its position in Calithera Biosciences by 25.8% in the 3rd quarter. Wells Fargo & Company MN now owns 33,742 shares of the biotechnology company’s stock worth $531,000 after purchasing an additional 6,910 shares during the period. 72.19% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Calithera Biosciences (CALA) Downgraded by BidaskClub to “Strong Sell”” was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.com-unik.info/2018/01/19/calithera-biosciences-cala-downgraded-by-bidaskclub-to-strong-sell.html.

Calithera Biosciences Company Profile

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Analyst Recommendations for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit